Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$538M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$379M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$337M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.14B |
| 2 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$466M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$420M |
| 4 |
Tesla
TSLA
|
+$251M |
| 5 |
IPHI
INPHI CORPORATION
IPHI
|
+$242M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.39% |
| 2 | Financials | 7.95% |
| 3 | Communication Services | 5.87% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Healthcare | 5.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CIVI
2826
DELISTED
Civitas Resources
CIVI
| $731K | ﹤0.01% |
15,528
-13,831
| -47% | -$561K |
|
2827
Celldex Therapeutics
CLDX
$3.26B
| $730K | ﹤0.01% |
21,825
-33,474
| -61% | -$919K |
|
|
RWT
2828
Redwood Trust
RWT
$592M
| $730K | ﹤0.01% |
60,545
-90,126
| -60% | -$1.01M |
|
2829
Vanda Pharmaceuticals
VNDA
$305M
| $729K | ﹤0.01% |
33,890
-63,808
| -65% | -$1.14M |
|
|
VSA
2830
VisionSys AI
VSA
$12.7M
| $729K | ﹤0.01% |
+105
| New | +$895K |
|
2831
Agilysys
AGYS
$3.03B
| $728K | ﹤0.01% |
12,804
-14,403
| -53% | -$745K |
|
2832
LeMaitre Vascular
LMAT
$1.84B
| $728K | ﹤0.01% |
11,931
-13,769
| -54% | -$731K |
|
|
VIVO
2833
DELISTED
Meridian Bioscience Inc
VIVO
| $727K | ﹤0.01% |
32,754
-28,183
| -46% | -$598K |
|
|
ESPR
2834
DELISTED
Esperion Therapeutics
ESPR
| $726K | ﹤0.01% |
34,306
-3,714
| -10% | -$89.4K |
|
|
HA
2835
DELISTED
Hawaiian Holdings, Inc.
HA
| $725K | ﹤0.01% |
29,769
-30,842
| -51% | -$796K |
|
2836
AngioDynamics
ANGO
$639M
| $724K | ﹤0.01% |
26,666
-22,977
| -46% | -$561K |
|
2837
Hamilton Lane
HLNE
$5.55B
| $722K | ﹤0.01% |
7,924
-23,257
| -75% | -$2.11M |
|
2838
ICF International
ICFI
$1.72B
| $722K | ﹤0.01% |
8,216
-10,438
| -56% | -$955K |
|
2839
Malibu Boats
MBUU
$565M
| $722K | ﹤0.01% |
9,854
-11,921
| -55% | -$949K |
|
2840
PUT
Bath & Body Works
BBWI
$4.11B
| $721K | ﹤0.01% |
12,370
| – | – |
|
2841
PUT
Medtronic
MDT
$110B
| $720K | ﹤0.01% |
5,800
| – | – |
|
2842
Mueller Water Products
MWA
$4.19B
| $720K | ﹤0.01% |
49,989
-99,628
| -67% | -$1.43M |
|
|
SCS
2843
DELISTED
Steelcase
SCS
| $720K | ﹤0.01% |
47,673
-81,105
| -63% | -$1.17M |
|
2844
CALL
American International
AIG
$41.7B
| $719K | ﹤0.01% |
15,100
| – | – |
|
|
FFIC
2845
DELISTED
Flushing Financial
FFIC
| $719K | ﹤0.01% |
33,536
-5,425
| -14% | -$123K |
|
|
SAFE
2846
DELISTED
Safehold Inc.
SAFE
| $718K | ﹤0.01% |
9,146
-20,354
| -69% | -$1.47M |
|
2847
Innoviva
INVA
$1.48B
| $717K | ﹤0.01% |
53,444
-47,782
| -47% | -$598K |
|
2848
Domo
DOMO
$184M
| $716K | ﹤0.01% |
8,856
-20,157
| -69% | -$1.32M |
|
2849
Apogee Enterprises
APOG
$911M
| $714K | ﹤0.01% |
17,533
-22,179
| -56% | -$836K |
|
2850
Standard Motor Products
SMP
$905M
| $714K | ﹤0.01% |
16,467
-16,534
| -50% | -$740K |
|
Similar funds
Barclays's Q2 2021 Portfolio in Review
As of Q2 2021, Barclays held 5,234 positions worth $212B, up 14% from $186B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Barclays deployed $11.1B of net new capital in Q2 2021, opening 558 new positions and adding to 1,559 existing holdings. Its largest new stake was Proofpoint, Inc.: 1,241,690 shares worth $216M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 13% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.14B trimmed.
- Barclays's largest Q2 2021 buy was Proofpoint, Inc.: 1,241,690 shares worth $216M.
- Barclays added most to iShares US Real Estate ETF in Q2 2021, an estimated $1.48B increase.
- Barclays's biggest Q2 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.14B.
- Barclays fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $466M.
- Barclays's ten largest holdings make up 36% of its $212B portfolio in Q2 2021.
- Barclays opened 558 new positions and closed 327 in Q2 2021.
- Barclays's portfolio value rose 14% quarter-over-quarter to $212B.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.